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Abstract
Objective : To determine the prevalence of malignant ovarian 
germ cell tumour in term of characteristics, management, 
and 3-year survival rate in Dr. Cipto Mangunkusumo Hospital 
Jakarta from 2011 to 2013.
Methods : This is a cross-sectional study. Secondary data 
were collected from medical record as well as interviewing 
patients through phone call or home visit.
Results : We collected data from 24 subjects. As many as 
54.2% of subjects were between 20 to 40 year old, and 58.3% 
was single. Around 83.3% of the subjects came with chief 
complaint of abdominal enlargement. Histopathology fi nding 
confi rmed dysgerminoma in 50% subjects, mixed ovarian 
germ cell tumour in 25%, endodermal sinus tumour or yolk 
sac tumour in 16.7%, and immature teratoma in 8.3%. Half 
of the cases were found in stage I. The primary therapy was 
conservative surgical staging and adjuvant chemotherapy.In 
2 subjects with dysgerminoma, neoadjuvant chemotherapy 
(bleomycin, etoposide, cisplatin, and cyclophosphamide-
cisplatin regimen) resulted in a good response. The 3-year 
survival rate was 83.3% in dysgerminoma, 100% in mixed 
ovarian germ cell tumour, and 50% in immature teratoma.
Conclusions : In malignant ovarian germ cell tumour, 
conservative surgical staging followed by a complete course 
of chemotherapy is the treatment of choice with 3-year 
survival rate exceeding 70%.
Keywords : dysgerminoma, non-epithelial ovarian 
tumour,ovarian germ cell tumour, survival.
Abstrak
Tujuan : Mengetahui sebaran meliputi karateristik, 
penatalaksanaan dan kesintasan 3 tahun pasien tumor 
ganas sel germinal ovarium di RSCM tahun 2011 – 2013.
Metode : Penelitian ini menggunakan studi potong lintang 
dengan mengambil data sekunder dari rekam medis dan 
mewawancarai pasien atau keluarga pasien via telepon atau 
kunjugan rumah.
Hasil : Pada penelitian ini, dari 24 subjek penelitian, 
54,2% ditemukan pada usia 20-40 tahun dan 58,3% 
subjek belum menikah. Sebanyak 83,3% datang dengan 
keluhan perut membesar. Secara histopatologi didapatkan 
jenis disgeminoma, tumor sel germinal campuran, sinus 
endodermal (yolk sac) dan teratoma imatur dengan proporsi 
masing-masing 50%, 25%, 16,7% dan 8,3%, sebagian besar 
kasus (50%) ditemukan pada stadium I. Conservative 
surgical staging dan kemoterapi adjuvan tatalaksana pilihan. 
Terdapat 2 subjek jenis disgerminoma yang diberikan dengan 
kemoterapi neoadjuvan (regimenbleomycin, etoposide, 
cisplatin dan cyclophosmide-cisplatin) memberikan respon 
yang baik. Kesintasan ≥ 3 tahun pada jenis disgerminoma 
mencapai 83,3%, pada tumor sel germinal campuran 100% 
dan pada teratoma imatur mencapai 50%.
Kesimpulan : Pada tumor ganas sel germinal ovarium 
conservative surgical staging diikuti kemoterapi lengkap 
merupakan pilihan terapi dengan kesintasan ≥ 3 tahun 
mencapai > 70%.
Kata kunci : disgerminoma,kesintasan, tumor ovarium non 
epithelial, tumor sel germinal ovarium.
INTRODUCTION
Around 70% of ovarian tumour that affects 
teenager and young adult is ovarian germ 
cell tumour and one-third of the total cases is 
malignant.1Malignant ovarian germ cell tumour 
is a rare occurrence, accounts for 5% of total 
ovarian malignancy.2Unlike malignant neoplasm 
from epithelial ovary cells, this type of tumour 
affects women in reproductive age, including 
teenager and young adult.
According to Surveillance, Epidemiology and 
Results (SEER) in 1973 to 2003, identifi cation in 
1,262 patients with malignant ovarian germ cell 
tumour showed dysgerminoma in 32.4% cases, 
immature teratoma with malignant degeneration 
in 35.6% cases, and mixed germ cell tumour in 
28.7% cases.3In Asian and African population, the 
most common type of malignant ovarian germ 
cell tumour is dysgerminoma.4
Management in malignant ovarian germ cell 
tumour has improved dramatically, giving rise 
to improvement in survival rate. Survival rate 
reaches 100% in dysgerminoma type and 85% in 
non-dysgerminoma type.5 Treatment in ovarian 
germ cell tumour used to result in impaired 
fertility.6In the 1980s, reserving fertility could only 
be performed in stage 1 and 2 malignant ovarian 
germ cell tumour with normal contralateral ovary 
and uterus. Starting in 1989, fertility function 
could be well maintained in all stage of the 
tumour, even in patients with involvement of 
both ovaries.7
Compared to data on testicle germ cell tumour, 
data in Indonesia regarding ovarian germ cell 
tumour is scarce. Therefore, we collected and 
analyzed the data to determine the prevalence 
and management of malignant ovarian germ cell 
in Indonesia, especially in Jakarta.
METHODS
This is a cross-sectional study. Secondary 
data were collected from the medical record 
and from interviewing patients. The interview 
was performed via phone call or home visit to 
determine the 3-year survival rate. We recruited 
all patients with malignant ovarian germ cell 
tumour who received a complete course of 
therapy in Dr. Cipto Mangunkusumo Hospital 
Jakarta from 2011 to 2013.
We calculated the sample size based on prior 
data on disease prevalence in Asia. The result 
was 49 subjects. Subjects were recruited with 
total sampling from cancer registration in the 
oncology division of Obstetrics and Gynecology 
Department. Collected data were analyzed with 
the Statistical Program for Social Sciences (SPSS) 
20. Ethical clearance was obtained from the Health 
Research Ethics Committee, Faculty of Medicine, 
Universitas Indonesia, in August 2017.
RESULTS
There were 57 patients with malignant ovarian 
germ cell tumour in Cipto Mangunkusumo 
Hospital Jakarta from 2011 to 2013. However, 
only 24 subjects fulfi lled the inclusion criteria 
of having a complete medical record. Baseline 
characteristics of the subjects are presented in 
table 1.
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Table 1.Subjects Baseline Characteristics and Histo-
pathology Finding
Variables (n : 24)
Age (yo)
10-19
20-40
≥ 40
Marital status
Single
Married
Parity
0
≤ 2
> 2
Chief complaint
Abdominal enlargement
Abdominal pain
Ultrasound/chest X-ray
No ascites and effusion
Ascites or effusion
Ascites and effusion
Histopathology
Dysgerminoma
Mixed germ cell tumour
Endodermal sinus 
tumour (yolk sac) 
Immature teratoma
1
13
10
14
10
14
7
3
20
4
12
9
3
12
6
4
2
n %
1
13
10
14
10
14
7
3
20
4
12
9
3
12
6
4
2
Table 2. Tumor Marker Findings
Table 3. Clinical Staging Grouped by Histopathology Type.
Variables
Variables
Dysgerminoma (n : 12)
Elevated LDH
Elevated Ca125
Elevated bHCG
Elevated LDH, Ca125
Elevated LDH, AFP, bHCG
Mixed germ cell tumor
Elevated LDH
Elevated Ca125
Endodermal sinus tumor
Elevated AFP
Elevated AFP, Ca125
Elevated AFP, LDH, Ca125 
Immature teratoma (n : 2)
Elevated LDH
Dysgeminoma (n : 12)
Stage 1
Stage 3
Stage 4
Mixed germ cell tumor (n : 6)
Stage 1
Stage 3
Endodermal sinus tumor (n : 4)
Stage 1
Stage 2
Immature teratoma (n : 2)
Stage 1
Stage 3
6
2
1
2
1
3
3
2
1
1
2
8
2
2
4
2
2
2
1
1
50 
16.7 
8.3 
16.7 
8.3 
50 
50 
50 
25 
25 
100
66.7
16.7
16.7
66.7
33.3
50 
50 
50
50
n
n
%
%
We also collected data on tumour marker 
examination. Most of the subjects with 
dysgerminoma had raised the level of lactate 
dehydrogenase (LDH). We found two (16.7%) 
subjects with cancer antigen 125 (CA125) 
elevation, which is uncommon as Ca125 elevation 
is usually associated with the ovarian epithelial 
tumour. In three (25%) subjects, elevation in LDH 
was accompanied with other tumour marker 
elevation such as alpha-fetoprotein (AFP), human 
Chorionic Gonadotrophin (bHCG) and CA125. 
Another signifi cant elevation of a tumour marker 
is presented in Table 2.
Furthermore, we noted clinical staging from 
each subject grouped by type of histopathology 
fi ndings, as shown in Table 3.
In term of case management, unilateral 
salphingo-oophorectomy (USO) was 
performed in half of the total subjects with or 
without omentectomy, appendectomy, and 
lymphadenectomy.
Options for chemotherapy were grouped 
based on histopathology type of the tumour. Half 
of the subjects with dysgerminoma underwent 
complete series of cisplatin, vinblastine, and 
bleomycin (PVB); bleomycin, etoposide, and 
cisplatin (BEP); and cyclophosphamide-cisplatin 
(CP) with the proportion of 8.3%, 25%, and 16.7% 
consecutively. The rest of the subjects did not 
undergo chemotherapy.
In term of 3-year survival rate, most of the 
patients (70.8%) were alive, and 83.3% were 
asymptomatic.
We analyzed survival functions with Kaplan 
Meier curve and found that all patients with stage 
3 and 4 tumour despite their histopathology 
type had a 3-year survival rate of 100% with 
treatment. Similarly, the 3-year survival rate 
for patients with neoadjuvant chemotherapy is 
100%. We also found that 3-year survival rate 
in dysgerminoma with complete treatment is 
higher than endodermal sinus tumour, immature 
teratoma, and mixed germ cell tumour.
DISCUSSION
The highest prevalence of malignant ovarian germ 
cell tumour was found in age 20 to 40 year old, 
followed by those older than 40, and younger than 
20. This fi nding agrees with prior epidemiological 
data in which the highest incidence of malignant 
ovarian germ cell tumour occurs in young females 
aged 15 to 30-year-old.8However, one study 
stated that the highest incidence is within 15 to 
19 year old.3 Up until 20 years old, almost 70% of 
ovarian tumour originates from germ cells, and 
one-third of this number proves to be malignant.6 
The tendency of malignancy in younger age may 
be caused by a hormonal factor as in the high 
level of exogenous and endogenous estrogen 
that disturbs the development of germ cell 
from primitive to mature cells. These abnormal 
germ cells are retained until puberty in which 
gonadotropin further initiates proliferation and 
results in tumour with various histopathology.9
In this study, most of the patients came with a 
chief complaint of abdominal enlargement. This 
is inconsistent with several other studies that 
presented abdominal pain and distention as their 
chief complaints.10,11
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We found that most of our subjects 
had dysgerminoma. This is consistent 
with epidemiology data from   that stated 
dysgerminoma as the most frequent type of 
malignant ovarian germ cell tumour.10Another 
important fi nding we need to highlight is tumour 
marker test. Carcinoembryonic antigen (CEA) is 
associated with gastrointestinal tract tumour. 
However, 4 of our subjects underwent this 
test that we think is unnecessary. Elevation in 
CA125 may be caused by various factors since 
this tumour marker is usually associated with 
ovary epithelial cell tumour. Each of our subjects 
underwent a test for multiple types of tumour 
markers, and therefore, we found overlapping 
results. However, we only presented results with 
signifi cant elevation.
Study on tumour marker  found that there 
were 7 signifi cant tumour markers associated with 
various type of germ cell tumour in ovary. CA125 
was found in more than 50% of the subjects. AFP 
was found positive mostly in endodermal sinus 
tumour (100%), immature teratoma (61.9%), and 
dysgerminoma (11.8%). Signifi cant elevation of 
LDH was found in 95% of dysgerminoma cases 
and 83.3% of endodermal sinus tumour. CEA is 
considered not associated with germ cell ovary 
tumor.12
Half of our subjects did not present with ascites 
or effusion. This condition may be caused by the 
fact that ascites or peritonitis due to effusion is a 
secondary manifestation from torsion, infection, 
or ovarian tumour rupture.13
Unilateral Salphingo-Oophorectomy (USO) 
was performed in 50% subjects in which 5 of them 
underwent additional procedures (omentectomy, 
appendectomy, and / or lymphadenectomy) 
due to the younger age and marital status of 
most subjects. One subject underwent bilateral 
salphingo-oophorectomy (BSO), and 11 subjects 
underwent total hysterectomy with BSO. In a study 
by Weinberg et al in 2011, USO was performed 
in 67.5% patients while total hysterectomy with 
BSO in 25% of patients. This study only examined 
subjects with surgery and preserved fertility.5
In term of histopathology, dysgerminoma, 
mixed germ cell tumour, endodermal sinus 
tumour, and immature teratoma, more than 50% 
were found in stage I. This fi nding agrees with 
epidemiology data which stated that 60-70% 
cases were FIGO stage I or II.11
Malignant ovarian germ cell tumour is 
sensitive to chemotherapy. The standard regimen 
for non-dysgerminoma cases is BEP.14 In a study, 
75% of patients with adjuvant chemotherapy 
postoperatively, 77% received BEP regimen. One 
patient with immature teratoma stage IIIc grade 
2-3 was given additional VAC regimen when the 
tumour recurred.5 In our study, only 10 subjects 
completed 6 series of chemotherapy, 8 of them 
had adjuvant chemotherapy (6 with PEB regimen, 
1 with PVB regimen, and 1 with CP regimen) while 
the remaining 2 had neoadjuvant chemotherapy 
with BEP and CP regimen. Both groups presented 
a satisfying result.
We did not fi nd any VAC regimen in our data. 
There are no recurrent cases, and therefore we 
never used VAC regimen. Three patients with 
dysgerminoma had total abdominal radiotherapy, 
and 10 patients (5 with dysgerminoma and 5 with 
immature teratoma) did not receive postoperative 
adjuvant therapy unless 1 patient with stage Ia 
dysgerminoma with recurrence.5 In our study, we 
did not examine radiotherapy treatment, and we 
did adjuvant chemotherapy for dysgerminoma, 
mixed germ cell tumour, endodermal sinus 
tumour, and immature teratoma patients 
although chemotherapy was only performed in 
42% subjects.
Overall survival rate was 100%. Based on 
epidemiology data, the majority of patients with 
ovarian germ cell malignancy has high cured rate 
with a small proportion experiencing recurrence 
within 24 months after primary diagnosis.14As 
many as 71% of our subjects survived for at least 
3 years after surgery. Based on histopathology 
type, dysgerminoma, mixed germ cell tumour, 
and immature teratoma had a 3-year survival 
rate of 83.3%, 100%, and 50% consecutively. 
Endodermal sinus tumour cases had a less-than-
3-year survival rate of 100%.
We had 7 subjects who had survival duration 
of less than 3 years. This event may be caused by 
a certain tendency to refuse chemotherapy. We 
did not examine the recurrence or progression of 
the disease.
This study examined rarely evaluated 
epidemiology data. There is no recent data on 
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characteristic, management, and survival rate of 
patients with malignant germ cell tumour of the 
ovary, especially in Dr. Cipto Mangunkusumo 
Hospital Jakarta. Furthermore, there is no 
standard management guideline for such cases. 
However, we are also aware of a weakness in this 
study. In particular, we had inadequate subjects. 
The sample size was calculated with a minimal 
of 49 subjects. We only managed to recruit 24 
subjects due to incomplete medical record data. 
We were unable to contact patients to learn 
about their current condition. Patients who live 
out of town presented as a challenge because 
we cannot perform the necessary physical and 
supporting examination to detect recurrence. 
Without routine follow-up, we lost contact from 
most of our patients.
CONCLUSION
Malignant ovarian germ cell tumour occurs mostly 
in teenagers, and young adult (20 to 40-year-old) 
and the most common type is dysgerminoma. 
Tumour marker elevation may differ based on 
histopathology. In dysgerminoma, mixed germ 
cell tumour, and immature teratoma, we found 
elevation in LDH while elevated AFP was found in 
endodermal sinus tumour.
All type of malignant ovarian germ cell 
tumour is mostly detected in stage I. Unilateral 
salphingo-oophorectomy (conservative surgical 
staging) followed with adjuvant chemotherapy 
(BEP regimen) is still the treatment of choice, 
especially for nulliparous patients. With adequate 
treatment (surgery and chemotherapy), patients 
with malignant ovarian germ cell tumour had 
71% 3-year survival rate.
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